Oragenics Develops Automated Intranasal Device for Treating Concussed Patients
The device is intended for initial treatment in the acute settingSARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc....
Clinical Trial
CytoDyn Announces Start of Preclinical MASH Study, Results Expected in Fall 2024
VANCOUVER, Washington, June 27, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing...
Femasys to Participate in European Society of Human Reproduction and Embryology 40th Annual Meeting in Amsterdam
Leading women’s reproductive health conference directly follows the company’s EU CE Mark approval for four of its productsATLANTA, June 27,...
Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues...
Tourmaline Bio Announces the Promotion of Ryan Robinson to Chief Financial Officer
NEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing...
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company...
Rezolute Announces Exercise of Underwriters’ Option to Purchase Additional Shares and Concurrent Private Placement
Additional $6.7M in funding resulting in approximately $67M in gross proceedsNEW YORK, June 27, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc....
Daré Bioscience Announces Reverse Stock Split
Shares Expected to Begin Trading on Split-Adjusted Basis on July 1, 2024 SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) --...
Spectral AI Surpasses 90% of Pediatric Enrollment Target in Burn Centers for Pivotal U.S. Burn Study
DALLAS, June 27, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence...
Annovis Bio Files Provisional Patent for New Manufacturing Process of Crystalline Form of Buntanetap
MALVERN, Pa., June 27, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”),...
Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT Trial
Enrollment in SUMMIT Part 2 remains on track for completion in Q2 2025 with top-line results expected by end of...
INmune Bio, Inc. Completes Blinded Interim Analysis of Phase II Alzheimer’s Disease Trial
The planned interim analysis confirms the accuracy of the sample size calculations and statistical power for EMACC, the primary endpoint....
GRI Bio Announces Pricing of $4 Million Public Offering
LA JOLLA, CA, June 27, 2024 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a...
BioAtla to Host Virtual R&D Day on Clinical Program and Pipeline Updates on July 25, 2024
SAN DIEGO, June 27, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the...
Quoin Pharmaceuticals Announces International Expansion of Ongoing Clinical Trials for Netherton Syndrome
Clinical site to be Opened in Saudi Arabia Site Currently Treating Netherton Patients Who Are Eligible for...
Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
Boston (June 27, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company...
First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind
The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-controlled trial conducted...
BioRestorative Therapies Announces Notice of Allowance for Patent Covering Fundamental Aspect of ThermoStem® Metabolic Disease Program
– Adds to comprehensive patent portfolio underlying novel ThermoStem® technology platform – – Expanding intellectual property estate expected to help...
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
8 Out of 10 Newly Diagnosed OSA Patients Choose Oral Appliance Therapy Over CPAP and Preferred Vivos’ Flagship CARE Oral...
Arch Biopartners Announces GMP Manufacturing of Cilastatin Drug Product
TORONTO, June 27, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF),...